Cegid Positioned as the Leader and Ace Performer in the SPARK MatrixTM: Unified Retail Commerce Platform, 2025 by QKS Group
The QKS Group SPARK Matrix™ evaluates vendors based on the parameters of technology excellence and customer impact. It offers an in-depth analysis of the global market dynamics, major trends, vendor landscapes, and competitive positioning. By providing a competitive analysis and ranking of leading technology vendors, SPARK Matrix™ delivers strategic insights that help users assess provider capabilities, differentiate competitively, and understand market positions.
Cegid is recognized as a technology leader & ace performer in the 2025 SPARK Matrix for Unified Retail Commerce Platform (URCP) owing to its strong expertise in enabling real-time, cross-channel retail operations. The Cegid retail platform is noted for its ability to unify in-store and digital experiences through a centralized architecture that supports inventory visibility, order management, clienteling, and POS integration. Designed to address the operational challenges of global retailers, Cegid enables consistent customer experience, Agile fulfillment, and streamlined store operations across multiple geographies. Its composable capabilities, native mobility, and scalable cloud infrastructure make it a preferred choice for retail enterprises seeking to modernize legacy systems and drive omnichannel execution with operational clarity.
QKS Group defines Unified Retail Commerce Platform (URCP) as an 'integrated, real-time solution that consolidates all retail operations, including point-of-sale (POS), e-commerce, mobile commerce, order management, supply chain logistics, customer relationship management (CRM), and financial reconciliation into a single, real-time operational framework.' The platform includes real-time inventory management, dynamic order orchestration, unified customer profiles, and API-first adaptability, enabling scalability and cross-channel optimization. Additionally, URCP enhances operational efficiency, reduces IT complexity, and improves the customer experience through advanced personalization capabilities.
'Cegid's unified retail commerce platform addresses a critical gap in the retail technology stack by centralizing store operations, inventory visibility, and customer engagement into a single, scalable system,' says Prakhar Bansal, Analyst at QKS Group. 'Its modular architecture, real-time data synchronization, and strong POS-clienteling integration make it particularly effective for retailers operating across multi-format and multi-country environments. Cegid stands out for its focus on operational execution-bridging front-end experience with back-end efficiency to support consistent omnichannel delivery.'
'We are incredibly proud to be recognized as a 'Leader' in this global study by QKS Group. This distinction highlights not only the strength of our technology platform, but also our ability to support retailers in their international expansion—while ensuring local compliance and operational excellence. Most importantly, it's the trust and collaboration of our clients that drive us forward. They inspire us to keep innovating and delivering intelligent, unified solutions that elevate their retail experience worldwide.' said Nathalie Echinard, General Manager of Retail Business Division at Cegid.
The Unified Retail Commerce Platform market is experiencing accelerated growth as retailers seek to eliminate channel silos and build cohesive, data-driven customer journeys. Advancements in API-first architecture, real-time data synchronization, and composable commerce are driving platform consolidation across POS, inventory management, clienteling, order orchestration, and customer engagement. The adoption of unified commerce strategies is further fueled by the need to support cross-channel fulfillment models, localized pricing, and consistent customer experiences across regions and store formats. As retailers prioritize operational agility, data unification, and store digitization, unified retail commerce platforms are emerging as foundational infrastructure for scalable, customer-centric retail transformation.
Additional Resources: For more information, visit Cegid
About Cegid:
Cegid is a European leading provider of cloud business management solutions for finance (cash-flow, tax, ERP), human resources (payroll, talent management), CPAs, retail and entrepreneurial sectors. With a solid full cloud business model, Cegid provides long-term commitment to its customers, superior and distinctive experiences and helps companies of all sizes accelerate their digital business transformation, locally and worldwide. Cegid combines a forward-thinking and pragmatic approach of the business with strong capacity to innovate, an in-depth expertise in new technologies such as artificial intelligence and an understanding of regulations and compliance. In today's rapidly changing world, Cegid makes more possible by helping customers unleash their potential thanks to innovative and purposeful business solutions.
Bolstered by its strong international ambition and reach, its 500,000 customers, Cegid has 4,400 employees and sells its solutions in 130 countries. Cegid reported revenues of €967 million (as of December 31, 2024). Pascal Houillon has been the CEO since March 2017.
For more information: www.cegid.com/en/
About QKS Group:
QKS Group is a global advisory and consulting firm focused on helping clients achieve business transformation goals with Strategic Business and Growth advisory services. At QKS Group, our vision is to become an integral part of our client's business as a strategic knowledge partner. Our research and consulting deliverables are designed to provide comprehensive information and strategic insights for helping clients formulate growth strategies to survive and thrive in ever-changing business environments.
For more available research, please visit https://qksgroup.com/
Media Contact:
QKS GroupShraddha Roy PR & Media RelationsRegus Business Center 35 Village Road, Suite 100, Middleton Massachusetts 01949 United States
Email: [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Biofuels Market Size to Exceed USD 326.42 Bn by 2034 Growing Need for Clean Energy is Driving Biofuels Adoption
The global biofuels market size is predicted to increase from USD 110.9 billion in 2025 and is anticipated to be worth around USD 326.42 billion by 2034, expanding at a CAGR of 11.4% from 2025 to 2034. A study published by Statifacts a sister firm of Precedence Research. Ottawa, July 02, 2025 (GLOBE NEWSWIRE) -- According to Statifacts, the global biofuels market size was evaluated at USD 110.9 billion in 2024 and is estimated to attain USD 326.42 billion by 2034, growing at a CAGR of 11.4% during the forecast period from 2025 to 2034. Government initiatives for favorable regulatory measures and research endeavors, growing dependence on greenhouse gas emissions, and rising popularity as an eco-friendly fuel for road transportation are driving the growth of the market. This Report is Readily Available for Immediate Delivery, Visit Here to Explore the Report Sample and In-depth Databook Now@ Biofuels Market Overview The biofuels market refers to the production, distribution, and application of biofuels, which are liquid fuels produced from renewable biological sources, including plants and algae. Biofuels offer a solution to one of the challenges of wind, solar, and other alternative energy sources. Biofuels are fuels derived directly or indirectly from biomass. Biofuel benefits include supporting agriculture, rural development, reducing greenhouse gases, low pollution, economic stimulation, efficiency, renewable energy, low emissions, energy security, and reducing foreign oil dependence. The biofuels market growth is driven by government initiatives for suitable regulatory measures & research endeavors, growing dependence on reducing greenhouse gas emissions, rising demand for eco-friendly fuel for road transportation, and technological advancements. There is no emission of hazardous gases like sulfur dioxide (SO) and carbon monoxide (CO). By using biofuels instead of fossil fuels, there is only the emission of non-toxic materials, which reduces the risk of cancer and breathing problems in human beings. Biofuels Market Highlights North America dominated the global market with the largest market share in 2024. Asia Pacific is estimated to expand the fastest CAGR between 2025 and 2034. By fuel type, the bioethanol segment accounted for a considerable share of 72.1% in 2024. By feedstock, the vegetable oil segment registered its dominance over the global market share of 27.7% in 2024. Major Trends in the Biofuels Market What Is the Market Trend for Biofuels Market? Government initiative for suitable regulatory measures: The government policy on biofuels encourages the setting up of a supply chain mechanism for biodiesel production from short gestation crops, used cooking oil, and non-edible oilseeds. The roles and responsibilities of all the concerned departments or ministers concerning biofuels have been captured in the policy document to synergise efforts. India aims to achieve 20% ethanol blending with petrol by 2025-26, largely achieved through 1G ethanol from sugar cane and food grains. Global governments are offering a variety of incentives and enacting regulations to promote biofuel adoption. Technological advancements: Technological advancements in the biofuel industry, electro-fuels, which is a spark-ignited revolution in green hydrogen, synthetic biology designing the future molecules of green energy, waste-to-energy transforming trash into transportable fuel, and algae to oils, a green option, reshaping energy policies. Along with satisfying basic energy requirements, they reduce greenhouse gas emissions, provide energy security, and support regional development. The latest advancements in biofuels include advancements in enzyme technology, fermentation improvement, and the creation of integrated biorefineries capable of producing many streams of biofuel and bioproducts. Technological advancements promote the production and processing of biofuels. Ready to Dive Deeper? Visit Here to Buy Databook & In-depth Report Now@ Is Biofuel a Growing Industry? Yes, the biofuel industry is a growing one due to increasing research and development undertakings by both research institutions and biotechnology companies alike, along with high demand for cleaner fuels, pushed by the global switch to more sustainable and renewable energy forms. Regulatory support: Regulatory support for biofuels adoption, renewable fuel standards (RFS) create a stable and predictable market for biofuel manufacturers, the actuality furnished with the aid of government mandates fosters greater funding in biofuel technologies and infrastructure, and by using biofuels, the RFS allows less harmful emissions, contributing to international climate dreams. Government Policies Driving Biofuel Growth | Advance Biofuel Rising demand: Rising demand for biofuels is contributing to the growth of the biofuels market. Biofuels are green fuels in that they do not contribute to the carbon dioxide (CO2) burden. Biofuel is biodegradable and non-toxic. Unlike renewable diesel, petroleum diesel is derived from a non-renewable resource that will not run out. Growing dependence on reducing greenhouse gas emissions: Due to compatibility with the natural carbon cycle, bio-fuels offer the most beneficial alternative for reducing greenhouse gases from the transportation sector. The benefits of reducing greenhouse gas emissions' impacts on the world include a cut in consumption, regulatory compliance, enhanced stakeholder relations, enhanced external relations, cost savings, slowed climate change, economic growth, and air quality. Replacing fossil fuels with biofuels has the potential to reduce some undesirable environmental impacts of fossil fuel production and use, including conventional & greenhouse gas (GHG) pollutant emissions, exhaustible resource depletion, and dependence on unstable foreign suppliers. Role of Artificial Intelligence (AI) in the Biofuels Market Artificial intelligence (AI) role in biofuels provides an emerging and significant convergence in the relationship between advanced technology and energy produced from renewable sources. Many aspects of biofuel production are transformed by AI's data analytics, modelling & prediction abilities, and machine learning, from maximizing biomass utilization and increasing fuel production to improving methods of production and providing the preservation of the environment. AI in biofuels is used for improving biofuel production, such as adjusting irrigation and fertilizer usage to increase yield, conversion process, such as temperature adjusting, and improving pressure levels to improve the efficiency of biofuels. An AI-driven system can improve every stage, helping farmers to grow better feedstocks, enhancing production methods, ensuring fuel quality, and even reducing environmental impacts through smart assessments. Revolutionizing Renewable Energy: AI-Based Solutions for Sustainable Biofuel | IEEE Conference Publication | IEEE Xplore What are the Significant Achievements of the Leading Industrial Firms? According to a report published in September 2024, Petroleum Minister Hardeep S Puri Highlighted India's Bioenergy Progress at India Bio-Energy and Tech Expo 2024. Ethanol blending percentage surges from 1.53% in 2014 to 15% in 2024. E100 fuel launched at over 400 retail outlets nationwide. Puri urges the transport minister, Gadkari, to promote the production of E-100-compatible vehicles. Press Release: Press Information Bureau In May 2025, a landmark achievement in its efforts to deliver clean, locally sourced biofuels in Africa was announced by Jord, the Swedish renewable energy company. The Municipal Council of Sakar, located in Senegal's Sedhiou region, has allocated 300 hectares of land to Jord Africa. This allocation is part of a larger 1000-hectare plan that signals a strong commitment from both the company and local authorities to transform underutilized land into a hub for clean energy production. Jord launches Senegal biofuel project with 300 hectare land allocation - GreentechLead How Does IoT Act as an Opportunity for the Biofuels Market? The Internet of Things (IoT) in the energy sector presents a significant opportunity in the biofuels market, enhancing the operational efficiency, reliability, and sustainability of energy systems. It also helps integrate renewable energy sources, ensure better supply-demand response, and use energy more efficiently. For renewable energy sources, production levels fluctuate based on weather patterns and environmental conditions. IoT devices help to mitigate this variability by offering real-time monitoring and control. IoT technology improves the efficiency of smart grids by collecting real-time data on energy usage and grid performance. This information enables utilities to balance supply and demand effectively, integrate renewable energy solutions, and allow dynamic pricing models. The main purpose of IoT is to connect a multitude of devices and objects to the internet. This connectivity allows these devices to collect, share, and analyze information in real time. This IoT is a critical part of the technological development that is paving the way for a sustainable future. By integrating with renewable energy, environmental compliance, smart cities, waste management, agriculture, and energy management, IoT is having a deep impact on the health of our planet. Limitations and Challenges in the Biofuels Market What are the Potential Concerns Related to the Biofuels Market? Engine compatibility issues: The problems with biofuel engines include biodiesel may contain some 'unconverted' vegetable oil (incomplete processing), traces of chemicals from the making of the biodiesel can remain in the biodiesel. The engine either refuses to start in cold weather or runs only for a few seconds after starting. Biofuels are considered environmentally friendly; their increased water content and oxygen can cause corrosion and damage to fuel system components. Deposits and clogging because of biodiesel have been widely reported, but are generally traceable to biodiesel that is either of low quality or has become oxidized. Using Biodiesel Fuel in Your Engine High production costs: The cost of biofuel production is influenced by many factors, like feedstock selection, labor and land costs, the oil market, and agricultural subsidies. Technological advancements like CELF and advanced enzymatic hydrolysis drive efficiency and cost-effectiveness. The costs of biofuels mainly depend on labor and land costs, feedstock, oil market, and agricultural subsidies. Biofuels are more expensive than petrol. With the current price hikes in many of the feedstocks used for biofuels like cereals, vegetable oils used cooking oil, and animal fats, the price difference to fossil fuels is becoming ever larger. How Did North America Dominate the Biofuels Market in 2025? North America dominated the global biofuels market in 2025. Growing initiatives for suitable regulatory measures & research endeavors, growing dependence on reducing greenhouse gas emissions, and increasing popularity as an eco-friendly fuel for road transportation are driving the growth of the market in the North American region. How Do Biofuels Act as a Key to the Future of Renewable Energy in the United States? The United States holds the fourth-largest global refining capacity and ranks as the seventh-largest exporter of refined petroleum products. The United States is the leading biofuel producer in the World. According to a report published in July 2024 by IEA Bioenergy on biofuels production and development in the United States, the U.S. biofuel production capacity rose to 23.8 billion gallons per year (BGPY) in 2023, a growth of over 1.7 billion gallons compared to 2022. Ethanol production has reached 17.8 BGPY since 2023, while biodiesel production capacity stands at 2.1 BGPY, and renewable diesel capacity is now 3.9 BGPY. Biofuels production and development in the United States – Bioenergy What To Expect from Asia Pacific's Biofuel Market? Asia Pacific is anticipated to grow at the fastest rate in the market during the forecast period. Trend towards contactless interactions, the healthcare sector's expansion, growing adoption of cloud technology, and increasing demand for automation in appointment management are contributing to the biofuels market in the Asia Pacific region. How Do Biofuels Act as a Key to the Biofuels Market in India? The main source of biofuel is ethanol, which is primarily produced from sugarcane. Overall, ethanol from sugarcane remains the main source of biofuel used in India. In March 2025, according to the Minister of Petroleum and Natural Gas, India has emerged as the world's third-largest biofuel producer. India has achieved 19.6% ethanol blending in petrol as of January and is on track to reach 20%, five years ahead of its original 2030 target. Biofuels Market Scope Report Attribute Key Statistics Market Size in 2025 USD 141 Billion Market Size by 2034 USD 257.6 Billion Growth Rate from 2025 to 2034 CAGR of 6.9% Largest Market North America Fastest Growing Market Asia Pacific Base Year 2024 Forecast Period 2025 to 2034 Segments Covered By Fuel Type, By Feedstock, and By Region Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Biofuels Market Segmentation Fuel Type Insights Biofuels Market Size by Fuel Type 2024 to 2034 (USD Million) Segment 2024 2025 2034 Biodiesel 37,031.4 39,802.5 79,377.0 Ethanol 95,103.4 1,01,201.1 1,78,224.2 What Made Bioethanol the Dominant Segment in the Biofuels Market in 2024? The bioethanol segment underwent notable growth in the market during 2024. Bioethanol is a fuel made from plant material like sugarcane or corn. It is produced by fermenting the sugars in the plants with yeast to produce ethanol and carbon dioxide. Bioethanol can be used in many ways, including producing ethanol-based fuel spray to clean industrial equipment and fuel in vehicles modified to run on it. Benefits of bioethanol include reducing air pollution, reducing dependence on crude oil, helping to reduce greenhouse gas emissions, mitigating global warming, and more. Bioethanol | Definition, Production Process, Uses, & Benefits The biodiesel fuel type segment is expected to grow at the fastest rate in the market during the forecast period of 2025 to 2034. Using biodiesel fuel as a vehicle fuel improves public health and the environment, as it provides safety benefits and contributes to a resilient transport system. Biodiesel in its pure, unblended form causes far less damage than petroleum diesel if released or spilled to the environment. Feedstock Insights Biofuels Market Size by Feedstock 2024 to 2034 (USD Million) Segments 2024 2025 2034 Coarse Grains 35,999.2 38,125.4 65,589.2 Non-agri Feedstock 11,729.8 12,703.4 25,817.6 Biomass 8,834.2 9,555.0 19,247.6 Vegetable oil 36,565.5 38,889.8 69,228.6 Sugar crop 22,300.6 23,729.9 42,407.4 Jatropha 3,688.4 4,248.2 12,133.9 Others 13,017.2 13,751.9 23,176.9 How the Vegetable Oil Segment Dominated the Biofuels Market in 2024? The vegetable oil segment enjoyed a prominent position in the market during 2024. Vegetable oils are used as a substitute for fossil fuels. Vegetable oils are the basis of biodiesel, which can be used like conventional diesel. Biodiesel is produced from vegetable oil by transesterification, a process that converts fats and oils into biodiesel and glycerin. Recycled used vegetable oil is used to produce renewable fuels, which are clean and therefore help minimize pollution. Carbon dioxide emissions are reduced when substituting traditional fuels with renewable fuels. The jatropha segment is projected to experience the highest growth rate in the market between 2025 and 2034. Benefits of jatropha as a biofuel include its resilience to harsh environmental conditions, adaptability to marginal lands, and ability to produce high yields of oil-rich seeds, making it a valuable resource for addressing the global energy crisis. The oil extracted from jatropha seeds can be converted into biodiesel, a renewable fuel alternative to fossil fuels. Browse More Research Reports: The global biogas market size accounted for USD 43,055 million in 2024 and is expected to exceed around USD 94,688 million by 2034, growing at a CAGR of 8.2% from 2024 to 2034. The global bioethanol market size was estimated at USD 86.5 billion in 2024 and is projected to be worth around USD 124.16 billion by 2034, growing at a CAGR of 3.68% from 2025 to 2034. The global fuel storage tank market size accounted for USD 15,400 million in 2024 and is expected to exceed around USD 24,610 million by 2034, growing at a CAGR of 4.8% from 2024 to 2034. The global gasoline fuel additives market size was USD 214.15 million in 2023, calculated at USD 226.14 million in 2024 and is expected to reach around USD 389.96 million by 2034, expanding at a CAGR of 5.6% from 2024 to 2034. The global octane improver fuel additives market size was USD 98 million in 2023, calculated at USD 103.49 million in 2024 and is expected to reach around USD 178.46 million by 2034, expanding at a CAGR of 5.6% from 2024 to 2034. Ready to Dive Deeper? Visit Here to Buy Databook & In-depth Report Now@ Competitive Landscape in the Biofuels Market BTG International Ltd.: This company is an international specialist healthcare company that is developing and commercializing products targeting critical care, cancer, and other disorders. Renewable Energy Group, Inc.: This company is a leader in the biofuels industry, providing lower-carbon fuel solutions to fleets. Abengoa Bioenergy S.A.: This company is a global leader in the development of new industrial biotechnologies and debuts an advanced biorefinery for cellulosic ethanol in Southwest Kansas. Cargill: Cargill is committed to providing food, ingredients, agricultural solutions, and industrial products to nourish the world in a safe, responsible, and sustainable way. DowDuPont, Inc.: It is a leader in Agriculture and Specialty Products, combining the complementary portfolios, resources, and capabilities of heritage Dow and DuPont. Wilmar International Ltd: Wilmar International Ltd's business activities include oil palm cultivation, edible oils refining, oilseeds crushing, consumer-packaged edible oils processing and merchandising, specialty fats, oleochemicals, biodiesel manufacturing, gains processing and merchandising, and sugar milling and refining. POET, LLC: This is a US biofuel company that specializes in the creation of bioethanol. Archer Daniels Midland Company: They are a global leader in human and animal nutrition and the world's premier agricultural organization and processing company. VERBIO Vereinigte BioEnergie AG: They produce biofuels and chemical products from rapeseed oil, rye, wheat, triticale, maize, and straw. My Eco Energy: They specialize in creating renewable fuel solutions and green energy innovations. China Clean Energy Inc.: This is a biodiesel and specialty chemical producer operating in the People's Republic of China and selling products both domestically and worldwide. What Are the Latest Advancements in Biofuels? In May 2025, the forthcoming release of BioxiGuard, Japan's first antioxidant specially developed for marine biodiesel fuel ('biofuel'), was announced by an NYK Group Company specializing in chemical R&D as well as the manufacture and sale of chemical products, Nippon Yuka Kogyo Co., Ltd. NYK Group Company Launches Japan's First Antioxidant for Marine Biodiesel Fuel | NYK Line In April 2025, 'Scheme for Implementation of Biofuel Projects in Madhya Pradesh', under the Madhya Pradesh Renewable Energy Policy, 2025, was officially launched by the Madhya Pradesh Government in a significant move towards a sustainable future. Madhya Pradesh Launches Biofuel Scheme to Boost Sustainability - Asia Pacific | Energetica India Magazine Segments Covered in the Report By Fuel Type Biodiesel Bioethanol By Feedstock Coarse Grain Non-agri Feedstock Biomass Vegetable Oil Sugar Crop Jatropha Others By Geography North America U.S. Canada Europe Germany France United Kingdom Rest of Europe Asia Pacific China Japan India Southeast Asia Rest of Asia Pacific Latin America Brazil Rest of Latin America Middle East & Africa (MEA) GCC North Africa South Africa Rest of Middle East & Africa You can place an order or ask any questions, please feel free to contact us at sales@ Statifacts offers subscription services for data and analytics insights. This page provides options to explore and purchase a subscription tailored to your needs, granting access to valuable statistical resources and tools. Access here - Contact US Ballindamm 22, 20095 Hamburg, Germany Web: Europe: +44 7383 092 044 About US Statifacts is a leading provider of comprehensive market research and analytics services, offering over 1,000,000 market and custoer data sets across various industries. Their platform enables businesses to make informed strategic decisions by providing full access to statistics, downloadable in formats such as XLS, PDF, and PNG. For Latest Update Follow Us: Our Trusted Data Partners: Precedence Research | Towards Healthcare | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Dental | Towards EV Solutions | Nova One AdvisorError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
an hour ago
- Associated Press
I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Company to host investor event on Tuesday, July 8th ROCKVILLE, Md., July 02, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the presentation of positive Phase 1b combination data for givastomig, in combination with nivolumab and mFOLFOX6, at the European Society for Medical Oncology Gastrointestinal Cancers Congress 2025 (ESMO GI 2025) in Barcelona (abstract #388MO) . Givastomig is a bispecific antibody targeting Claudin 18.2 and 4-1BB. I-Mab plans to host a virtual investor event on Tuesday, July 8th (register here ) to review these data. The Phase 1b data (NCT04900818) show a confirmed objective response rate (ORR) of 71% across all doses (12/17), and 83% (10/12) at doses selected for the ongoing dose expansion study (8 mg/kg and 12 mg/kg). Responses occurred in tumors with low levels of PD-L1 expression and/or Claudin 18.2 (CLDN18.2) expression, with favorable overall tolerability. There were no Grade 3 or greater events for nausea and vomiting, and only one Grade 3 TRAE for increased liver enzymes. The data are based on the results of the dose escalation part of a Phase 1b study evaluating the givastomig combination as first line therapy (1L) in patients with Claudin 18.2-positive gastric cancers (≥1+ IHC staining intensity in ≥1% of tumor cells). The primary endpoint is safety. The study enrolled only patients in the U.S. 'The positive Phase 1b combination data presented at ESMO GI bolster our confidence in givastomig's potential to be a best-in-class Claudin 18.2 directed therapy. Givastomig has been well tolerated when combined with immuno-oncology and chemotherapy, has shown a high objective response rate, with rapid onset and durable responses that have deepened over time, supported by consistent pharmacokinetic data and soluble 4-1BB induction,' said Phillip Dennis, MD, PhD, Chief Medical Officer of I-Mab. 'In addition, we are optimistic about the results from the 8 mg/kg and 12 mg/kg doses. These doses showed an ORR of 83%, with consistent responses across PD-L1 and Claudin 18.2 expression levels, and a favorable overall safety profile. These data further our conviction in the ongoing Phase 1b dose expansion study. We believe givastomig has broad potential in a number of gastric cancer settings and look forward to continued advancement of the program.' 'I am encouraged by the response rates, as well as the deepening of responses over time, demonstrated by the givastomig combination regimen in the Phase 1b dose escalation study that we presented today at ESMO GI. Despite approved therapies, targeted treatment options for gastric cancers continue to be limited. While the data are early, givastomig combination therapy demonstrates a high response rate across Claudin 18.2 and PD-L1 expression levels,' said Samuel J Klempner, MD, Associate Professor of Medicine at Massachusetts General Hospital. 'In addition, I have been pleased to observe that givastomig has a favorable overall tolerability profile with a low level of gastrointestinal side effects -- especially important for patients with gastric cancer. I look forward to participating in the ongoing givastomig clinical development program, and hope we may be able to expand the population of patients who may benefit from Claudin 18.2 directed agents.' Virtual Investor Event: Register ( here ) for the Post-ESMO GI 2025 Investor Event to be held on Tuesday, July 8th at 2:00 PM EDT. A replay of the webinar will be accessible on the Events page of the I-Mab website for 90 days. Fireside Chat Event with Lucid Capital Markets to Recap the Presentation: Tune in ( here ) for a fireside chat sponsored by Christopher Liu, PharmD, Managing Director at Lucid Capital Markets that will be accessible today at 2:00pm EDT on the Events page of the I-Mab website. A replay of the fireside chat will be available for 90 days. ESMO GI Presentation Details: A full copy of the ESMO GI presentation is available on the Publications and Presentations page of the I-Mab website here. Givastomig Phase 1b Dose Escalation Data Summary in 1L Gastric Cancers Patient Characteristics: Efficacy Results: Durability: Safety: About Givastomig Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting Claudin 18.2 (CLDN18.2)-positive tumor cells. It conditionally activates T cells through the 4-1BB signaling pathway in the tumor microenvironment where CLDN18.2 is expressed. Givastomig is being developed for first line (1L) metastatic gastric cancers, with further potential in other solid tumors. In Phase 1 trials, givastomig has shown promising anti-tumor activity attributable to a potential synergistic effect of proximal interaction between CLDN18.2 on tumor cells and 4-1BB on T cells in the tumor microenvironment, while minimizing toxicities commonly seen with other 4-1BB agents. An ongoing Phase 1b study is evaluating givastomig for the treatment of gastric cancer in the 1L setting in combination with standard of care, nivolumab (an anti-PD-1 checkpoint inhibitor) plus chemotherapy, in dose escalation and dose expansion cohorts. Dose escalation is complete, and enrollment in the first dose expansion cohort (n=20) finished ahead of schedule. Enrollment continues to progress ahead of schedule in the second dose expansion cohort (n=20). The study builds on positive Phase 1 monotherapy data. Givastomig is being jointly developed through a global partnership with ABL Bio, in which I-Mab is the lead party and shares worldwide rights, excluding Greater China and South Korea, equally with ABL Bio. About I-Mab I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. The Company's differentiated pipeline is led by givastomig, a potential best-in-class, bispecific antibody (Claudin 18.2 x 4-1BB) designed to treat Claudin 18.2-positive gastric cancers. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed for first-line metastatic gastric cancers, with additional potential in other solid tumors. In Phase 1 trials, givastomig was observed to maintain strong tumor-binding and anti-tumor activity, attributable to a potential synergistic effect of proximal interaction with Claudin 18.2 and 4-1BB, while minimizing toxicities commonly seen with other 4-1BB agents. For more information, please visit and follow us on LinkedIn and X. I-Mab Forward Looking Statements This announcement contains forward-looking statements. These statements are made under the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'will', 'expects', 'believes', 'designed to', 'anticipates', 'future', 'intends', 'plans', 'potential', 'estimates', 'confident', and similar terms or the negative thereof. I-Mab may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the SEC), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about I-Mab's beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the Company's pipeline and clinical development of I-Mab's drug candidates, including givastomig; the projected advancement of the Company's portfolio and anticipated milestones and related timing; the Company's expectations regarding the impact of data from ongoing and future clinical trials; the timing and progress of studies and trials (including with respect to patient enrollment); the potential benefits of givastomig; and the availability of data and information from ongoing studies and trials. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: I-Mab's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or New Drug Application/Biologics License Application (NDA/BLA) approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of I-Mab's drug candidates; I-Mab's ability to achieve commercial success for its drug candidates, if approved; I-Mab's ability to obtain and maintain protection of intellectual property for its technology and drugs; I-Mab's reliance on third parties to conduct drug development, manufacturing and other services; and I-Mab's limited operating history and I-Mab's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the 'Risk Factors' section in I-Mab's annual report on Form 20-F filed with the SEC on April 3, 2025, as well as the discussions of potential risks, uncertainties, and other important factors in I-Mab's subsequent filings with the SEC. All forward-looking statements are based on information currently available to I-Mab. I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. I-Mab Investor & Media Contacts PJ Kelleher LifeSci Advisors +1-617-430-7579 [email protected] [email protected]
Associated Press
an hour ago
- Associated Press
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Fortrea Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action
NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fortrea Holdings, Inc. (NASDAQ: FTRE) between July 3, 2023 and February 28, 2025, both dates inclusive (the 'Class Period'), of the important August 1, 2025 lead plaintiff deadline. SO WHAT: If you purchased Fortrea securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Fortrea class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 1, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to Fortrea's 2025 earnings; (2) Fortrea overstated the cost savings it would likely achieve by exiting the transition service agreements ('TSAs'); (3) as a result, Fortrea's previously announced EBITDA targets for 2025 were inflated; (4) accordingly, the viability of Fortrea's post-Spin-Off business model, as well as its business and/or financial prospects, were overstated; and (5) as a result, Fortrea's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Fortrea class action, go to call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]
